This trial (n=16) investigated the interaction between MDMA (112mg/70kg) and pindolol (treatment for hypertension, beta-blocker) in 2001. The study tested this in a double-blind design (meaning all participants received MDMA).
The resulting study found that pindolol (20mg) prevented MDMA from raising heart rate but didn’t prevent a slight elevation of blood pressure.
Topic Healthy Subjects
Safety
Country Switzerland
Visit trial
Status
Completed
Results Published
Start date
01 June 2001
End date
01 March 2002
Chance of happening
100%
Phase
Phase I
Design
Blinded
Type
Interventional
Generation
First
Participants
16
Sex
Male
Age
18- 45
Therapy
No
Trial Details
MDMA (3,4-Methylenedioxymethamphetamine, "Ecstasy") produces tachycardia, hypertension, hyperthermia, and other acute adverse effects. Ecstasy use has also been associated with rare cardio- and cerebrovascular complications. The role of beta-blockers in treating cardiovascular and adverse effects of MDMA is unknown. In a double-blind placebo-controlled study, we investigated the interactive effects of the beta-blocker pindolol (20 mg) with MDMA (1.6 mg/kg) on heart rate, blood pressure, body temperature, and adverse effects in 16 healthy subjects.NCT Number NCT00895804
Sponsors & Collaborators
University of BaselThe University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti.
Heffter Research Institute
The Heffter Research Institute has been advancing psychedelics (psilocybin) as medicines since 1993.
Papers
Effects of a β-blocker on the cardiovascular response to MDMA (Ecstasy)This double-blind cross-over study (n=16) finds that pindolol (medication for hypertension, 20mg) prevents the heart-raising effects of MDMA (112mg/70kg) but not the elevation of blood pressure.